0
variable(s) selected download| Category | Variable name | variable label (+ explanatory notes) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient data | gebdat | Date of birth | ||||||||||||||||||||||||||||||
| Patient data | gesl | Sex |
valuelist
+
|
|||||||||||||||||||||||||||||
| Patient data | iacr | Counts following IACR rules for reporting incidence |
valuelist
+
|
|||||||||||||||||||||||||||||
| Patient data | incdat | Incidence date
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||||
| Patient data | incjr | Year of incidence
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||||
| Patient data | ink_ses | Median income in postal code area as a proxy for socioeconomic status (SES)
+
Available from 2010. Socioeconomic status (SES) reflects an individual's social position, which strongly influences health and is linked to life expectancy in good health. Research on SES and health typically uses indicators such as education, income, occupation, and material wealth. This variable uses income as a proxy for SES.
Income data by postal code area were obtained from Statistics Netherlands (CBS), with 2019 as the reference year, downloaded on 16 October 2023 via https://www.cbs.nl/nl-nl/dossier/nederland-regionaal/geografische-data
/gegevens-per-postcode.
Income is defined as the median disposable household income, adjusted for household size and composition. For each area, the median standardised household income was compared to the national distribution and classified into one of five groups: low, lower-middle, middle, upper-middle, or high. Income thresholds (in euros) are available at: https://www.cbs.nl/nl-nl/longread/diversen/2023/statistische-gegevens-per-vierkant-en-postcode-2022-2021-2020-2019/4-beschrijving-cijfers. Because postal code areas often have few households, CBS also
considered the 99% confidence interval of the median income. If this interval spans multiple groups, a new category was created to reflect the range (e.g., 'low to lower-middle'). Categories may partially overlap due to this approach. If the median income is based on fewer than 10 households, it is classified as 'unclassifiable'. CBS originally defined 12 income categories.
For this variable, these were reduced to three to simplify analysis and remove overlaps.
Key considerations:
- Income is a snapshot and does not reflect accumulated wealth.
- Data are aggregated by postal code area, which may include substantial variation.
- Household income is strongly age-dependent; analyses should compare individuals within the same age group.
- Median disposable income is considered valid for up to 10 years before and after the reference year (2019).
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Patient data | leeft | Age at incidence date | ||||||||||||||||||||||||||||||
| Patient data | mal | Previous or subsequent malignancies
+
Selection of malignancies to specify in the request:
-Period: Previous and/or subsequent malignancies, or based on a defined timeframe before or around the incidence date.
-Type: All cancer types in the NCR, or all malignant/invasive (excluding skin BCC), or a selection of specific tumour types.
NKR database content with full availability:
Period: Nationwide complete from 1989.
Exclusion criteria:
- Patients residing abroad at the time of incidence
- Basal cell carcinomas of skin and lip
- Second primary invasive and second non-invasive squamous cell carcinomas of the skin
- Adenocarcinoma in situ/high-grade dysplasia of colon, rectosigmoid and rectum
- Carcinoma in situ of the cervix
- Benign/borderline tumours, except: CNS tumours from 2001, Borderline ovarian tumours, AL amyloidosis from 2017, Polymorphic PTLD
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Patient data | mal_incdat | Incidence date of previous or subsequent malignancy | ||||||||||||||||||||||||||||||
| Patient data | mal_int | Interval between incidence date and date of previous or subsequent malignancy | ||||||||||||||||||||||||||||||
| Patient data | mal_tumsoort | Tumour type of previous or subsequent malignancy
+
Refers to the NCR tumour classification based on site, morphology, and behaviour. For more information, see: https://iknl.nl/nkr/registratie/tumorindeling
|
||||||||||||||||||||||||||||||
| Patient data | ovldat | Date of death | ||||||||||||||||||||||||||||||
| Patient data | post_cijf | Numeric part of the patient's postal code at the time of incidence | ||||||||||||||||||||||||||||||
| Patient data | vit_stat_dat | Date of vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||||
| Patient data | vit_stat_int | Interval between incidence date and date of vital status (days)
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||||
| Patient data | vit_stat | Vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | topo | Topography excluding sublocation
+
Location of the primary tumour according to ICD-O-3.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | topo_sublok | Topography including sublocation
+
Location and sublocation of the primary tumour according to ICD-O-3.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | later | Laterality |
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | morf | Morphology
+
Histological type of the tumour (first four digits of the ICD-O morphology code) according to ICD-O-3.2.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||
| Tumour data | morf_cat | Morphology (categories) |
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | gedrag | Behaviour
+
Tumour behaviour (fifth digit of the ICD-O morphology code).
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | diffgrad | (Differentiation) grade
+
Tumour differentiation grade (sixth digit of the ICD-O morphology code)
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | ct | cT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | cn | cN (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | cm | cM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | pt | pT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | pn | pN (TNM)
+
The TNM classification uses the edition applicable at the time of incidence.
Meaning of the last character in pN:
S: Result based only on sentinel node examination (sn)
I: Isolated tumour cells (ITC)
M: Micrometastases (mi)
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | pm | pM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | figo | FIGO stage derived from TNM
+
The FIGO classification, proposed by the International Federation of Gynecology and Obstetrics (FIGO), is used to stage gynaecological tumours and complements the TNM classification for malignant tumours.
Cervical tumours:
Tumours up to incidence year 2021 are staged using FIGO 2009, based solely on clinical parameters. From 2021 onwards, FIGO 2018 applies, incorporating clinical, pathological, and imaging parameters, with pathology taking
precedence. For stage IIIC, the diagnostic basis is shown in figo_diag_basis.
Ovarian tumours:
Tumours up to incidence year 2017 use FIGO 1988; from 2017 onwards, FIGO 2014 applies. Both rely on pTNM, supplemented by cTNM if pTNM is unknown. If pre-surgical therapy is given, cTNM replaces pTNM. Clinically
confirmed metastases conut as metastases even without pathological confirmation.
Endometrial tumours:
Tumours up to incidence year 2010 use FIGO 1988; from 2010 onwards, FIGO 2009 applies. Both rely on pTNM, supplemented by cTNM if unknown. If pre-surgical therapy is given, cTNM replaces pTNM. Clinically confirmed
metastases count as metastases even without pathological confirmation.
Vulvar tumours:
Tumours up to incidence year 1999 use FIGO 1988; from 1999-2009, FIGO 1994 applies; from 2010 onwards, FIGO 2009 applies. All rely on pTNM, supplemented by cTNM if unknown. If pre-surgical therapy is given, cTNM replaces
pTNM. Clinically confirmed metastases count as metastases even without pathological confirmation.
|
||||||||||||||||||||||||||||||
| Tumour data | ond_swk_lat | Laterality of examined sentinel lymph nodes in the sentinel lymph node procedure
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | ond_lymf | Number of regional lymph nodes examined
+
All lymph nodes examined as part of initial diagnostics and treatment combined.
|
||||||||||||||||||||||||||||||
| Tumour data | ond_swk | Number of sentinel lymph nodes examined
+
Available since 2015.
|
||||||||||||||||||||||||||||||
| Tumour data | pos_swk_lat | Laterality of positive sentinel lymph nodes in the sentinel lymph node procedure
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | pos_lymf | Number of positive regional lymph nodes | ||||||||||||||||||||||||||||||
| Tumour data | pos_swk | Number of positive sentinel lymph nodes
+
Available since 2015.
|
||||||||||||||||||||||||||||||
| Tumour data | diag_basis | Basis for diagnosis
+
Non-microscopic confirmation:
0 = death certificate only
1 = clinical examination only (medical history and physical)
2 = clinical diagnostic tests, exploratory surgery or autopsy (without microscopic confirmation)
4 = specific biochemical and/or immunological laboratory tests.
Microscopic confirmation:
5 = haematological (bone marrow cytology, e.g., bone marrow aspiration, blood smear) or cytological confirmation of primary tumour or metastases, or definite microscopic confirmation but unclear whether cytology or histology
6 = histological confirmation of metastases only, including at autopsy
7 = histological confirmation of primary tumour, or unclear whether histology refers to primary tumour or
metastasis, including autopsy with histology.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | ingroei | Invasion into other anatomical structures
+
Available from 2015 for the following structures: urethra, vagina, anus, bladder, rectum, and parametrium
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | lvsi | Lymphovascular space invasion
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | meta_incdat | Incidence date of metastasis | ||||||||||||||||||||||||||||||
| Tumour data | meta_int | Interval between incidence date and date of metastasis (days)
+
The incidence date is defined as the date of the first histological or
cytological confirmation of the primary tumour.
The metastasis date refers to the first histological or cytological confirmation of the
metastasis. If histological confirmation does not occur within three
months, the clinical diagnosis date is used. Consequently, the
metastasis date may precede the primary tumour incidence date by up
to three months.
|
||||||||||||||||||||||||||||||
| Tumour data | meta_topo_sublok | Topography including sublocation of metastasis
+
Metastasis location according to ICD-O-3. Metastatic sites have been recorded nationwide since 2008. For distant metastases at more than three sites, C768 was coded up to 2014 to indicate more than three locations. In 2017/2018 C768 may indicate more than four locations.
Explanation for records where both cM and pM show no metastases despite metastatic sites being recorded at diagnosis: cTNM is based on information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan. pM indicates whether pathological
confirmation exists for distant metastases. If metastases are detected during or after neo-adjuvant treatment, TNM is not updated, but metastasis locations are recorded.
If the dataset includes metastasis locations after progression: only new or enlarged metastases are recorded, not all existing ones. C809 is coded for clinical progression when the site is unknown.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||
| Tumour data | meta_topo | Topography excluding sublocation of metastasis
+
Metastasis location according to ICD-O-3. Metastatic sites have been recorded nationwide since 2008. For distant metastases at more than three sites, C768 was coded up to 2014 to indicate more than three locations. In 2017/2018 C768 may indicate more than four locations.
Explanation for records where both cM and pM show no metastases despite metastatic sites being recorded at diagnosis: cTNM is based on information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan. pM indicates whether pathological
confirmation exists for distant metastases. If metastases are detected during or after neo-adjuvant treatment, TNM is not updated, but metastasis locations are recorded.
If the dataset includes metastasis locations after progression: only new or enlarged metastases are recorded, not all existing ones. C809 is coded for clinical progression when the site is unknown.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||
| Tumour data | multifoc | Tumour multifocality
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Tumour data | tum_lok | Tumour location
+
Available from 2025.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Process data | contact_zkh1 | Hospital of first contact regarding malignancy
+
The first hospital visited by the patient for symptoms related to the malignancy, and where, based on that visit, a (suspected) malignancy is determined.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Process data | hist_diag_type[1-2] | Type of histological diagnosis[1-2]
+
Available for cervical and endometrial cancer from 2015, and for vulvar cancer from 2018 onwards.
|
||||||||||||||||||||||||||||||
| Process data | ic_dagen | Number of days in intensive care
+
One day in the Intensive Care Unit (ICU) for monitoring purposes does not count as an ICU admission. If there are multiple ICU admissions, the days are added together.
This item has been available since 2015. From 2021 onward, this has been recorded only for DGOA hospitals and may therefore be incomplete.
|
||||||||||||||||||||||||||||||
| Process data | ic_reden | Reason for intensive care admission
+
One day in the Intensive Care Unit (ICU) for monitoring purposes does not count as an ICU admission.
This item has been available since 2015. From 2021 onward, this has been recorded only for DGOA hospitals and may therefore be incomplete.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Process data | letsel | Potential permanent injury
+
After a procedure; for example, the creation of a stoma following intestinal injury.
This item is available from 2015 onwards. From 2021, it has been recorded only for DGOA hospitals and may therefore be incomplete.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Process data | swk | Sentinel lymph node procedure performed |
valuelist
+
|
|||||||||||||||||||||||||||||
| Process data | swk_dat | Date of sentinel lymph node procedure | ||||||||||||||||||||||||||||||
| Process data | swk_int | Interval incidence date and date of sentinel lymph node procedure (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||
| Process data | swk_uitslag | Result of the sentinel lymph node procedure |
valuelist
+
|
|||||||||||||||||||||||||||||
| Process data | swk_zkh | Hospital where the sentinel lymph node procedure was performed |
valuelist
+
|
|||||||||||||||||||||||||||||
| Process data | transfusie | Blood transfusion during hospital admission
+
During the initial treatment pathway, at least one surgical procedure involved a postoperative blood transfusion.
This item has been available since 2015. From 2021 onwards, this item has been recorded only for DGOA hospitals and may therefore be incomplete.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Process data | zkh_patnum | Patient number in hospital | ||||||||||||||||||||||||||||||
| Risk factors | asa | ASA classification
+
Available from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci | Charlson Comorbidity Index (weighted)
+
The yes/no variables for categories are summarised in cci_cat (0, 1, 2 or more) and cci (weighted score per
Charlson 1987), with some categories counted only once if both occur:
• Cerebrovascular disease and Hemiplegia
• Diabetes and Diabetes with end organ damage
• Mild liver disease and Moderate/severe liver disease
• Any tumour and Metastatic solid tumour
Alternative summary scoring methods may also be used.
Incomplete scores:
From 2019, registration aligns with the Charlson Comorbidity Index. Earlier records may lack complete category data, leading to some misclassification, noted in the relevant variable.
Note: From 1995 to 2014, comorbidities were recorded only in the southern Netherlands. From 2015, coverage is sometimes national but not for all tumour types or years. Missing variables indicate no comorbidities recorded for that tumour.
|
||||||||||||||||||||||||||||||
| Risk factors | cci_aids | AIDS (including HIV) according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_cat | Number of categories according to the Charlson Comorbidity Index
+
The yes/no variables for categories are summarised in cci_cat (0, 1, 2 or more) and cci (weighted score per
Charlson 1987), with some categories counted only once if both occur:
• Cerebrovascular disease and Hemiplegia
• Diabetes and Diabetes with end organ damage
• Mild liver disease and Moderate/severe liver disease
• Any tumour and Metastatic solid tumour
Alternative summary scoring methods may also be used.
Incomplete scores:
From 2019, registration aligns with the Charlson Comorbidity Index. Earlier records may lack complete
category data, leading to some misclassification, noted in the relevant variable.
Note: From 1995 to 2014, comorbidities were recorded only in the southern Netherlands. From 2015, coverage is sometimes national but not for all tumour types or years. Missing variables indicate no comorbidities recorded for that tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_chf | Congestive heart failure according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_collagenosis | Collagenosis according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_copd | Chronic obstructive pulmonary disease according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_cvd | Cerebrovascular disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2012: Cci_cvd did not include TIA but did include significant carotid stenosis (treated with carotid endarterectomy or carotid desobstruction). As a result, patients may have been incorrectly included or excluded from the cerebrovascular disease category.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_dementia | Dementia according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_dm | Diabetes mellitus according to the Charlson Comorbidity Index
+
From 2019 onwards, registration aligns with the Charlson Comorbidity Index For registrations from earlier years, not all categories can therefore be accurately determined. Up to around 2018: Diabetes managed by diet alone was included in the registration.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_eod_dm | Diabetes with end-organ damage according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_mild_liver | Mild liver disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2018: No distinction was made between mild and moderate or severe liver disease. These patients were all included under cci_liver1 instead of cci_liver2. This does not affect cci_cat but does affect category classification and CCI.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_severe_liver | Severe or moderate liver disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2018: No distinction was made between mild and moderate or severe liver disease. These patients were all included under cci_liver1 instead of cci_liver2. This does not affect cci_cat but does affect classification into categories and the CCI index.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_malignancy | Other malignancy according to the Charlson Comorbidity Index
+
Previous or concurrent invasive/malignant cancers, excluding basal cell and squamous cell carcinomas of the skin, where the initial diagnosis occurred between five years before and 30 days after the diagnosis of this tumou
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_metastatic | Other metastatic solid tumour according to the Charlson Comorbidity Index
+
Previous or synchronous metastatic cancer diagnosed up to 30 days after the diagnosis of this tumour. The NCR does not have complete registration of metachronous metastases. For many tumour types, these have only been recorded systematically or project-based in recent years, so this variable may sometimes incorrectly show as 0.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_mi | Myocardial infarction according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2012: Cci_mi also included angina pectoris, meaning patients may have been incorrectly included in this variable.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_plegia | Hemiplegia or paraplegia according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_pvd | Peripheral vascular disease according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_renal | Moderate or severe renal disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2018: Cci_renal also included mild kidney disease, meaning patients may have been incorrectly included in the category moderate or severe renal disease.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Risk factors | cci_ulcer | Ulcer disease according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chemo | Systemic chemotherapy classified as pre- or post-surgical
+
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local surgical procedures (e.g. polypectomy, excision biopsy, TUR, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chemo_code[1-n] | Code of systemic chemotherapy[1-n]
+
Systemic therapy drugs are recorded in the NCR using codes from the Anatomical Therapeutic Chemical classification system (ATC codes). Systemic therapy was not always recorded in detail; particularly before 2015, non-specific codes were used.
|
||||||||||||||||||||||||||||||
| Treatment data | chemo_start_int[1-n] | Interval incidence date and start date of systemic chemotherapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||
| Treatment data | chemo_stop_int[1-n] | Interval incidence date and stop date of systemic chemotherapy (days)[1-n]
+
The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||
| Treatment data | chemo_kuren | Number of cycles of systemic chemotherapy
+
Available since 2015.
|
||||||||||||||||||||||||||||||
| Treatment data | chemo_startdat[1-n] | Start date of systemic chemotherapy[1-n] | ||||||||||||||||||||||||||||||
| Treatment data | chemo_stopdat[1-n] | Stop date of systemic chemotherapy[1-n] | ||||||||||||||||||||||||||||||
| Treatment data | chemo_zkh[1-n] | Hospital where systemic chemotherapy was administered[1-n] | ||||||||||||||||||||||||||||||
| Treatment data | chemort | Chemoradiation classified as pre- or post-surgical
+
Both chemotherapy and radiotherapy were part of the treatment, and based on dates/types, this likely represents chemoradiation. The chemotherapy and radiotherapy components are also included in the variables for systemic chemotherapy and radiotherapy.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir | Surgery performed
+
Defined as surgery targeting the primary vulvar tumour. An additional resection or re-intervention is not included.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_compl_bloed | Surgical complication: bleeding
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery. The bleeding type is coded in cases of intraoperative blood loss of more than 1 litre or postoperative bleeding/haematoma.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_compl | Surgical complication
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_dat[1-4] | Date of surgery[1-4] | ||||||||||||||||||||||||||||||
| Treatment data | chir_compl_functiestoornis | Surgical complication: functional disorder
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_compl_infectie | Surgical complication: infection
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery. An infection may be at a local (e.g. abscess), organ-specific (e.g. adnexitis), or systemic (e.g. sepsis) level.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_int[1-4] | Interval between incidence date and date of surgery (days)[1-4]
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||
| Treatment data | chir_compl_letsel | Surgical complication: injury
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery. An example of an injury includes damage to major blood vessels or bowel obstruction.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_compl_lymf | Surgical complication: lymphatic
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery. Examples of the lymphatic type include lymphoedema, lymphocele, or a combination of both.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_compl_type_onbek | Surgical complication of unknown type
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_rad[1-3] | Radicality of surgery[1-3]
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_compl_reint | Re-intervention following a surgical complication
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: a new intervention (radiological, endoscopic, or surgical) was performed following a complication after surgery.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_compl_syst | Surgical complication: systemic
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery. Systemic type is coded in cases of a medication error or an adverse reaction to medication or a blood product.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_compl_tech | Surgical complication: technical
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery. A technical complication includes, for example, the retention of corpus alienum.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_compl_trombose | Surgical complication: thrombosis
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery. Examples of the thrombosis type include deep vein thrombosis of the leg or pelvis, or pulmonary embolism.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_type[1-4] | Type of surgery[1-4]
+
Defined as surgery targeting the primary vulvar tumour. An additional resection or re-intervention is not included.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_compl_wonddefect | Surgical complication: wound defect
+
Incompletely recorded since 2008.
From 2021 onwards, recorded only for DGOA hospitals. From 2023 onwards, recorded only for a subset of DGOA hospitals.
Value 1/yes: at least one complication occurred within 30 days after surgery. Examples of the wound defect type include wound dehiscence and burst abdomen (Platzbauch)
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | chir_zkh[1-4] | Hospital where surgery was performed[1-4] |
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | horm | Systemic hormonal therapy classified as pre- or post-surgical
+
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local surgical procedures (e.g. polypectomy, excision biopsy, TUR, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation)are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | lkd | Lymph node dissection performed
+
1=episode in bouwsteen. 0=episode niet in bouwsteen maar wel in kernbestand met incjr >= 1998
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | meta_chir | Surgery targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | meta_chir_code | Code for surgery targeting metastases | ||||||||||||||||||||||||||||||
| Treatment data | meta_chir_dat | Date of surgery targeting metastases | ||||||||||||||||||||||||||||||
| Treatment data | meta_chir_int | Interval between incidence date and date of surgery targeting metastases (days) | ||||||||||||||||||||||||||||||
| Treatment data | meta_rt | Radiotherapy targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | meta_chir_zkh | Hospital where surgery targeting metastases was performed | ||||||||||||||||||||||||||||||
| Treatment data | rt | Radiotherapy classified as pre- or post-surgical
+
This variable refers to radiotherapy targeting the primary tumour.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | rt_stop_int[1-n] | Interval between incidence date and end date of radiotherapy (days)[1-n] | ||||||||||||||||||||||||||||||
| Treatment data | rt_start_int[1-n] | Interval between incidence date and start date of radiotherapy (days)[1-n] | ||||||||||||||||||||||||||||||
| Treatment data | rt_startdat[1-n] | Start date of radiotherapy[1-n] | ||||||||||||||||||||||||||||||
| Treatment data | rt_stopdat[1-n] | End date of radiotherapy[1-n] | ||||||||||||||||||||||||||||||
| Treatment data | rt_type | Type of radiotherapy |
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | rt_zkh[1-n] | Hospital where radiotherapy was performed[1-n] | ||||||||||||||||||||||||||||||
| Treatment data | target | Systemic targeted therapy classified as pre- or post-surgical
+
This variable refers to systemic targeted therapy, including immunotherapy.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther | Tumour-directed therapy performed
+
Tumour directed therapy includes surgery of the primary tumour, radiotherapy and systemic therapy. Treatments targeting distant metastases only are not considered tumour directed therapy.
|
valuelist
+
|
|||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther_type | Type of tumour-directed therapy
+
This variable indicates the main tumour directed therapy, i.e. the primary therapy, for vulvar cancer. In addition to the primary tumour directed therapy, multiple other treatments may have been administered. Tumour directed therapy includes surgery of the primary tumour and systemic therapy. Treatments targeting distant metastases only are not considered tumour directed therapy.
|
valuelist
+
|